Anlotinib, a novel multitarget TKI which inhibits VEGF/VEGFR, PDGFRa/b, c-Kit, Ret, Aurora-B, c-FMS and DDR1 (27), showed antitumor activity in advanced liposarcoma in a multicenter phase II trial. Here, KDR is linked to liposarcoma.